PARP1 and ovarian carcinoma: Multiple studies have demonstrated that poly ADP-ribose polymerase (PARP) inhibitors exert a synthetic lethal effect on tumor cells harboring mutations in breast cancer-related genes (BRCA), bringing a new direction to the precision treatment of ovarian cancer (OC) (7).